Clinical Trial Update: Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ultralow-dose PET imaging with 18F-Florbetapir and 18F-Flutemetamol in Alzheimer’s disease and mild cognitive impairment; recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Dementia

Drugs mentioned

• AMYVID (Florbetapir F-18)
• VIZAMYL (Flutemetamol F-18)

Snippet

Sponsor: Akiva Mintz | Conditions: Alzheimer Disease, Mild Cognitive Impairment | Phase 2 | Status: RECRUITING